AstraZeneca today announced that Granta Park-based MedImmune, its global biologics research and development arm, has entered into a cancer research collaboration and licensing agreement with Immunocore, an Oxford biotech company.
The approach will be to use the power of the body’s own immune system to find and kill diseased cells, avoiding damage to healthy cells.